KS-133 是一种可穿过血脑屏障、具有 VIPR2 拮抗活性的双环肽,可选择性阻断 VIPR2 介导的 Gq/Ca、Gs/cAMP、cAMP/PKA/ERK 及 PI3K/AKT/GSK3β 信号通路,抑制小鼠前额叶皮层中由 VIPR2 激动剂诱导的 CREB 磷酸化,使巨噬细胞极化向 M1 偏移,减弱癌细胞增殖并降低 S-M 期细胞周期分布水平,在小鼠结直肠癌模型中具有抗肿瘤作用,可逆转精神疾病小鼠模型的认知衰退,可用于精神分裂症、结直肠癌、乳腺癌的相关研究。
产品编号: MS-T15058 纯度: 98.75% CAS No.: 2724212-01-3 分子式: C75H111N15O17S2 分子量: 1558.90
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

KS-133 是一种可穿过血脑屏障、具有 VIPR2 拮抗活性的双环肽,可选择性阻断 VIPR2 介导的 Gq/Ca、Gs/cAMP、cAMP/PKA/ERK 及 PI3K/AKT/GSK3β 信号通路,抑制小鼠前额叶皮层中由 VIPR2 激动剂诱导的 CREB 磷酸化,使巨噬细胞极化向 M1 偏移,减弱癌细胞增殖并降低 S-M 期细胞周期分布水平,在小鼠结直肠癌模型中具有抗肿瘤作用,可逆转精神疾病小鼠模型的认知衰退,可用于精神分裂症、结直肠癌、乳腺癌的相关研究。

生物实验数据

生物活性 KS-133 is a blood-brain barrier-penetrant bicyclic peptide with VIPR2 antagonistic activity that selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK, and PI3K/AKT/GSK3β signaling pathways, inhibits VIPR2 agonist-induced CREB phosphorylation in the mouse prefrontal cortex, shifts macrophage polarization toward M1, attenuates cancer cell proliferation and reduces the proportion of cells in S-M phase, exerts antitumor effects in a mouse colorectal cancer model, reverses cognitive decline in a mouse model of psychiatric disorders, and can be used for research on schizophrenia, colorectal cancer, and breast cancer.
体外研究
(In Vitro)

KS-133 (30 min) 可强效且选择性地拮抗人 VIPR2 介导的钙内流信号、cAMP 生成,IC50 分别为 24.8、500 nM。
KS-133 (1-10 μM; 3 days) 通过上调 iNOS 和 CXCL10 的表达、下调 Mrc-1 的 mRNA 表达,将 RAW264.7 小鼠巨噬样细胞极化为 M1 表型。
KS-133 (100 nM; 3 days) 可显著抑制血管活性肠肽 (VIP) 诱导的稳定过表达 EGFP 的 MCF-7 细胞增殖,使部分细胞的分裂减慢或停止。
KS-133 (100 nM; 24-48 h) 可阻断 VIP 诱导的 MCF-7 细胞向 S 期和 G2-M 期的进程,抑制 G1/S 期转换。
KS-133 (预孵育 3 h,随后与 VIP 共处理 10 或 3 h) 可抑制 VIP 诱导的 ERK、AKT 和 GSK3β 通路激活,并降低 MCF-7 细胞中 VIP 诱导的细胞周期蛋白 D1 水平。
KS-133 (预孵育 3 h,随后与 VIP 共处理 10 min) 可在稳定表达 VIPR2-EGFP 的 MCF-7 细胞中使 VIP 诱导的 PI3K 活性、 cAMP 生成量降低约 60% 和 40%,且不会改变 PI3Kγ 的表达。

Real Time qPCR

Cell Line: RAW264.7 murine macrophage-like cells
Concentration: 1, 3, 10 μM
Incubation Time: 3 days
Result: Significantly enhanced mRNA expression of the M1-type macrophage markers iNOS and CXCL10.
Significantly decreased mRNA expression of the M2-type macrophage marker Mrc-1.
Showed no significant effects on TNFα, IL-1Rn, or CCL22 mRNA expression.

Cell Proliferation Assay

Cell Line: MCF-7 cells stably overexpressing EGFP
Concentration: 100 nM
Incubation Time: 3 days
Result: Significantly decreased the proliferation of MCF-7 cells compared with untreated cells.
Slowed or halted cell division in some cells over 3 days of observation.

Cell Cycle Analysis

Cell Line: MCF-7 cells
Concentration: 100 nM
Incubation Time: 24 h; 48 h
Result: Attenuated VIP-induced increases in the percentage of cells in both S and G2-M phases, reducing the proportion of cells in the combined S-M phase from ~30% to ~12%.

Western Blot Analysis

Cell Line: MCF-7 cells
Concentration: 100 nM
Incubation Time: 3 h pre-incubation, then 10 min co-treatment with VIP; 3 h pre-incubation, then 3 h co-treatment with VIP
Result: Decreased VIP-induced phosphorylation of ERK1/2 (Thr202/Tyr204) by approximately 50%.
Decreased VIP-induced phosphorylation of AKT (Thr308) by approximately 70%.
Decreased VIP-induced phosphorylation of GSK3β (Ser9) by approximately 40%.
Decreased VIP-induced cyclin D1 protein levels by approximately 65%.

ELISA Assay

Cell Line: MCF-7 cells stably expressing VIPR2-EGFP
Concentration: 100 nM
Incubation Time: 3 h pre-incubation, then 10 min co-treatment with VIP
Result: Attenuated VIP-induced increases in cAMP levels to approximately 60% of that in KS-133-untreated cells.
体内研究
(In Vivo)

KS-133 (1 nmol/g;s.c.;单次; 每日 1 次;出生后第 1 至 14 天) 可阻断新生小鼠前额叶皮层中由 VIPR2 介导的 CREB 磷酸化,可在出生后早期 VIPR2 过度激活的小鼠模型中预防认知衰退与前额叶皮层神经元形态异常。
KS-133 (每只小鼠 30 μg;s.c.;每日 1 次;持续 3 周) 与 KS-133 纳米颗粒 (NPs) (每只小鼠 30 μg;皮下注射;每日 1 次/每 3 日 1 次;持续 3 周) 均展现出强效抗肿瘤作用;KS-133 NPs 可将肿瘤体积降至对照组的 38%,而未制剂化的 KS-133 联合抗 PD-1 抗体可将肿瘤体积降至对照组的 32%。
KS-133 (3 mg/kg,s.c.,每日 1 次,连续 14 天) 可显著改善精神分裂症小鼠模型的认知功能障碍 (表现为辨别指数升高),且 KS-133 可在脑区达到足以发挥 VIPR2 拮抗剂活性的浓度。

Animal Model: ICR (CD1) (male, postnatal day 12, 7-10 g, schizophrenia-related model via VIPR2 agonist Ro 25-1553 treatment); C57BL/6J (male, 8 weeks of age, 20-30 g, schizophrenia-related model via VIPR2 agonist BAY 55-9837 treatment);ICR (CD1) (male, treated from postnatal day 1 to 14, tested at 2-3 months of age, schizophrenia-related model via daily VIPR2 agonist Ro 25-1553 treatment from P1 to P14)
Dosage: 1 nmol/g; 20 nmol/mouse;1 nmol/g
Administration: s.c.; single simultaneous injection with Ro 25-1553; i.n.; single simultaneous injection with BAY 55-9837;s.c.; once daily; postnatal day 1 to 14, simultaneous with daily Ro 25-1553 injections
Result: Significantly reduced pCREB/CREB ratio and pCREB/β-actin ratio compared to the Ro 25-1553-only group.
Significantly reduced pCREB/CREB ratio and pCREB/β-actin ratio compared to the BAY 55-9837-only group.
Significantly increased the discrimination index in the novel object recognition test compared to the Ro 25-1553-only group, matching control levels.
Prevented Ro 25-1553-induced reductions in prefrontal cortex pyramidal neuron soma size, total apical and basal dendrite branch number, and total apical and basal dendrite length.
Reversed Ro 25-1553-induced reduction in dendritic complexity (decreased number of dendrite intersections at increasing distances from the soma) for both apical and basal dendrites via Sholl analysis.
Animal Model: BALB/cCrSlc (female, 6 weeks old, subcutaneous allograft tumor model)
Dosage: 30 μg/mouse (daily single agent); 30 μg/mouse (once every 3 days single agent); 30 μg/mouse (daily, combined with anti-PD-1 antibody)
Administration: s.c.; daily; 3 weeks; s.c.; once every 3 days; 3 weeks
Result: Reduced tumor volume to 66% of control group at day 21 (daily non-formulated KS-133).
Reduced tumor volume to 60% of control group at day 21 (daily KS-133 NPs).
Reduced tumor volume to 38% of control group at day 21 (KS-133 NPs administered once every 3 days).
Reduced tumor volume to 32% of control group at day 21 (daily non-formulated KS-133 combined with anti-PD-1 antibody).
Animal Model: early postnatal treatment with VIPR2 agonist Ro 25−1553 to induce schizophrenia model
Dosage: 3 mg/kg
Administration: s.c.; once daily; 14 days
Result: Increased discrimination index significantly compared to schizophrenia model vehicle control group.
Reached peak concentrations in brain regions at 1-2 hours post-administration: 0.054 μmol/kg in cerebral cortex, 0.058 μmol/kg in hypothalamus, 0.062 μmol/kg in hippocampus, 0.044 μmol/kg in striatum, and 0.103 μmol/kg in cerebellum.
性状 固体
颜色 White to off-white

化学信息

分子量 1558.90
分子式 C75H111N15O17S2
CAS No. 2724212-01-3

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (64.15 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.6415 mL3.2074 mL6.4148 mL16.0369 mL
5 mM0.1283 mL0.6415 mL1.2830 mL3.2074 mL
10 mM0.0641 mL0.3207 mL0.6415 mL1.6037 mL
15 mM0.0428 mL0.2138 mL0.4277 mL1.0691 mL
20 mM0.0321 mL0.1604 mL0.3207 mL0.8018 mL
25 mM0.0257 mL0.1283 mL0.2566 mL0.6415 mL
30 mM0.0214 mL0.1069 mL0.2138 mL0.5346 mL
40 mM0.0160 mL0.0802 mL0.1604 mL0.4009 mL
50 mM0.0128 mL0.0641 mL0.1283 mL0.3207 mL
60 mM0.0107 mL0.0535 mL0.1069 mL0.2673 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础